AliveDx Suisse S.A. (AliveDx) and Transmedic Indonesia, Thailand and Singapore have signed a second distribution agreement, enabling Transmedic to distribute the LumiQ® solution across these markets. The distribution agreement takes effect immediately.
This partnership underscores AliveDx’s dedication to expanding its global footprint and delivering clinical and economic value to clinicians, supporting faster diagnosis. Together, AliveDx and Transmedic will introduce new quality diagnostic solutions to the healthcare industry and further enhance patient care in Thailand, Indonesia, and Singapore.
The LumiQ solution will complement the MosaiQ® solution currently being distributed by Transmedic. The MosaiQ solution is a groundbreaking IVD platform for autoimmune diseases, allergies, and beyond. Its multiplexed, fully automated planar microarray technology enables syndromic testing for complex conditions. Designed for high throughput with continuous random access, the MosaiQ solution delivers fast, accurate results to meet the evolving demands of laboratory efficiency. Combined with LumiQ, the two platforms offer a seamlessly integrated, turnkey approach to screening and confirming autoantibodies across a wide range of diseases, simplifying workflows and improving efficiency.
“We are proud to announce our partnership with a key player in Thailand, Singapore and Indonesia. We are eager collaborate with Transmedic and to make a strategic impact on improving patients’ lives throughout the region,” said Manuel O. Méndez, CEO of AliveDx.
“We are thrilled to further strengthen our partnership with AliveDx through a second distribution agreement bringing the LumiQ solution alongside MosaiQ to our markets. This milestone expands our diagnostics portfolio and reinforces our mission to deliver groundbreaking solutions that make a lasting impact on patient care,” said Shawn Lee, CEO of Transmedic Group.
About Transmedic
Founded in 1980, Transmedic brings over 40 years of valuable industry experience, in-depth knowledge, and local expertise in cutting-edge medical technologies and treatments. Today, Transmedic is proud to be part of the EBOS Med Tech group, which also includes Australian Biotechnologies (allograft manufacturing), Cryomed (aesthetics division), and LifeHealthcare (ANZ distribution business). We are the leading independent medical technology distribution partner for world-class medical institutions and professionals in ASEAN and Hong Kong.
To learn more, please visit here
